Mechanisms by Which Complex Carbohydrates Influence Immune Imbalance in COPD via the Gut–Lung Axis: From Colonic Fermentation to Pulmonary Immune Responses

Why It Matters

Understanding carbohydrate‑driven metabolite signaling reveals a modifiable pathway to correct systemic immune imbalance in COPD, offering new nutritional or microbiome‑targeted therapeutic angles.

Key Takeaways

• Carbohydrate structure determines colonic fermentation speed and SCFA profile.
• Distal colon fermentation sustains butyrate, preserving gut barrier integrity.
• SCFAs modulate neutrophil recruitment and Treg/Th17 balance in lungs.
• Tryptophan metabolites support mucosal defense and epithelial repair.
• Bile acids link gastro‑esophageal reflux to lung microecology in COPD.

Pulse Analysis

The gut‑lung axis has emerged as a pivotal conduit through which dietary inputs reshape pulmonary immunity. In chronic obstructive pulmonary disease, systemic inflammation co‑exists with localized airway damage, and metabolites generated by gut microbes can travel via the bloodstream to modulate lung‑resident immune cells. By converting complex carbohydrates into short‑chain fatty acids and tryptophan‑derived compounds, the microbiota creates a biochemical bridge that influences neutrophil infiltration, macrophage activation, and the delicate Treg/Th17 equilibrium that underpins COPD progression.

The physicochemical makeup of ingested polysaccharides dictates where and how efficiently they are fermented. Simple, low‑polymerization fibers are rapidly broken down in the proximal colon, yielding a burst of acetate and propionate but leaving the distal colon starved of fermentable carbon. Conversely, highly branched or long‑chain fibers resist early degradation, allowing them to reach the distal colon where they sustain butyrate production. This prolonged saccharolytic activity preserves epithelial tight‑junction integrity, limits translocation of lipopolysaccharide, and maintains a favorable SCFA profile that can dampen systemic inflammation when delivered to the lungs.

These mechanistic insights open avenues for therapeutic innovation. Tailoring dietary fiber composition or employing prebiotic formulations could recalibrate SCFA and tryptophan metabolite outputs, directly addressing the immune dysregulation that fuels COPD exacerbations. However, quantitative links between gut‑derived metabolite concentrations, blood levels, and pulmonary effects remain underexplored in human cohorts. Rigorous clinical trials with synchronized sampling across the gut, circulation, and lung are essential to translate these findings into actionable interventions that complement existing inhaled therapies.